Sotera Health stock kpis
Want to see SHC full AI Analyst Report?
Net Revenue by Segment
Sotera Health reported net revenue by segment of $324.89M in Q3 2026, up 1.1% from Q2 2026 and up 4.4% year over year. This is the highest value since 2021.
Breaks down Sotera's revenue by business line, revealing which segments drive sales growth and where demand is strongest or weakest. A concentrated revenue base increases dependence on a few markets, while diversified growth across segments signals resilience. Tracking segment revenue trends highlights areas of pricing power, volume gains, or contract wins that are likely to shape future earnings.
Sterigenics is the clear growth engine—steady, accelerating top‑line and margin expansion driven by pricing and volume that underpins the raised outlook—while Nordion is a smaller, lumpy contributor whose outperformance reflects timing of Cobalt‑60 harvests and can reverse quarter‑to‑quarter. Nelson Labs is stable with low‑single‑digit growth and sequential margin recovery but still faces year‑over‑year cost pressure. Management’s increased CapEx and improving leverage support sustained capacity-driven growth, but FX volatility, inflationary costs and ongoing litigation are meaningful near‑term risks.
SHC Net Revenue by Segment
| Period | Sterigenics | Nordion | Nelson Labs | Total |
|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | $209.31M | $55.02M | $60.56M | $324.89M |
| Q2 2026Jun 30, 2026 | $211.57M | $49.15M | $60.66M | $321.38M |
| Q1 2026Mar 31, 2026 | $186.13M | $42.01M | $51.90M | $280.05M |
| Q4 2025Dec 31, 2025 | $198.41M | $49.83M | $55.20M | $303.44M |
| Q3 2025Sep 30, 2025 | $192.84M | $62.80M | $55.66M | $311.31M |
| Q2 2025Jun 30, 2025 | $194.84M | $42.43M | $57.07M | $294.34M |
| Q1 2025Mar 31, 2025 | $169.68M | $32.56M | $52.28M | $254.52M |
| Q4 2024Dec 31, 2024 | $179.43M | $56.79M | $53.98M | $290.20M |
| Q3 2024Sep 30, 2024 | $175.57M | $51.31M | $58.58M | $285.47M |
| Q2 2024Jun 30, 2024 | $176.35M | $41.24M | $59.00M | $276.59M |
| Q1 2024Mar 31, 2024 | $166.50M | $24.01M | $57.67M | $248.18M |
| Q4 2023Dec 31, 2023 | $172.20M | $79.83M | $58.21M | $310.24M |
| Q3 2023Sep 30, 2023 | $168.35M | $40.10M | $54.73M | $263.18M |
| Q2 2023Jun 30, 2023 | $166.59M | $31.98M | $56.72M | $255.28M |
| Q1 2023Mar 31, 2023 | $160.00M | $8.55M | $52.04M | $220.59M |
| Q4 2022Dec 31, 2022 | $161.67M | $34.09M | $55.83M | $251.59M |
| Q3 2022Sep 30, 2022 | $157.72M | $35.07M | $55.91M | $248.70M |
| Q2 2022Jun 30, 2022 | $157.79M | $50.48M | $58.37M | $266.64M |
| Q1 2022Mar 31, 2022 | $149.46M | $34.00M | $53.29M | $236.75M |
| Q4 2021Dec 31, 2021 | $150.18M | $36.70M | $54.37M | $241.25M |
| Q3 2021Sep 30, 2021 | $145.31M | $28.77M | $52.08M | $226.16M |
| Q2 2021Jun 30, 2021 | $145.18M | $49.13M | $57.61M | $251.92M |
| Q1 2021Mar 31, 2021 | $131.15M | $25.92M | $55.08M | $212.15M |

